{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:29:27Z","timestamp":1794475767562,"version":"4.9.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ygyno.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:30:26Z","timestamp":1777933826000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study"],"prefix":"10.1016","volume":"209","author":[{"given":"Fernanda B.","family":"Musa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirza Areli Calder\u00f3n","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warsha K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Hurteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Golembesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.04.012_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","article-title":"Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review","volume":"15","author":"Nag","year":"2022","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0020","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0025","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0035","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.22.01934","article-title":"PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel, Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Tew","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/14796694.2024.2441654","article-title":"Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer","volume":"21","author":"Salani","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/annonc\/mdy255","article-title":"Safety and dose modification for patients receiving niraparib","volume":"30","author":"Berek","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0065","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.04.012_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114157","article-title":"Tolerability of the niraparib individualized starting dose in the PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib first-line maintenance therapy","volume":"208","author":"Vulsteke","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.04.012_bb0075","series-title":"Prescribing Information","author":"Zejula (niraparib)","year":"2025"},{"key":"10.1016\/j.ygyno.2026.04.012_bb0080","series-title":"Database Characterization Guide","year":"2025"},{"key":"10.1016\/j.ygyno.2026.04.012_bb0085","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.012_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100044","article-title":"Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study","volume":"35","author":"Backes","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.04.012_bb0095","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of low- and moderate-grade adverse events in patients\u2019 treatment experience and treatment discontinuation: an analysis of the e1912 trial","volume":"42","author":"O\u2019Connell","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:59:22Z","timestamp":1794473962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826019578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"alternative-id":["S0090825826019578"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.04.012","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}